Clinical Trial Update: An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating nivolumab alone or with ipilimumab versus placebo in extensive-stage small cell lung cancer after platinum therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• nivolumab (nivolumab)
• nivolumab/ipilimumab

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2019-10-22